Nuformix plc is a UK-based pharmaceutical development company that specializes in treating fibrosis and oncology through drug repurposing. The company's main programs include NXP001, which is in the Phase 1-ready for oncology supportive care stage, and NXP002 in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. Nuformix is also developing NXP004 for the treatment of oncology. The company has an option agreement with Oxilio Ltd. for developing and exploiting NXP001 for the treatment of cancer. Founded in 2008, Nuformix is headquartered in London, UK.
Nuformix plc's ticker is NFX
The company's shares trade on the LSE stock exchange
They are based in London, England
There are 1-10 employees working at Nuformix plc
It is https://nuformix.com/
Nuformix plc is in the Healthcare sector
Nuformix plc is in the Biotechnology industry
The following five companies are Nuformix plc's industry peers: